IQVIA Holdings Inc. (NYSE:IQV) Position Cut by Fmr LLC

FMR LLC cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 60.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,137,512 shares of the medical research company's stock after selling 1,749,830 shares during the period. FMR LLC owned approximately 0.63% of IQVIA worth $223,533,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Synergy Asset Management LLC acquired a new position in shares of IQVIA during the 4th quarter worth $33,000. Lee Danner & Bass Inc. acquired a new position in IQVIA during the fourth quarter worth about $44,000. Zions Bancorporation N.A. increased its holdings in IQVIA by 55.2% in the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after buying an additional 85 shares in the last quarter. Versant Capital Management Inc raised its holdings in IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock worth $58,000 after purchasing an additional 93 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in shares of IQVIA in the 4th quarter worth about $60,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Performance

IQV stock traded down $2.86 during trading on Thursday, hitting $145.58. 650,246 shares of the company's stock traded hands, compared to its average volume of 1,390,407. The stock has a market capitalization of $25.67 billion, a price-to-earnings ratio of 19.38, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a 52 week low of $135.97 and a 52 week high of $252.88. The stock has a fifty day moving average price of $178.83 and a two-hundred day moving average price of $198.11. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Stephens assumed coverage on IQVIA in a report on Friday, December 20th. They set an "overweight" rating and a $250.00 target price on the stock. Citigroup lowered their target price on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Royal Bank of Canada reissued an "outperform" rating and set a $270.00 price target on shares of IQVIA in a research note on Monday, February 10th. BTIG Research downgraded IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. Finally, Robert W. Baird dropped their price target on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a research report on Tuesday, January 21st. Six investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, IQVIA currently has a consensus rating of "Moderate Buy" and a consensus price target of $241.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.